Hitomi Morishima

Guselkumab, a human interleukin‐23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52‐week, phase 3, multicenter, open‐label study

Shigetoshi Sano, Hiroshi Kubo, Hitomi Morishima et al. · The Journal of Dermatology · 2018 · 128 citations · Full text

Medicine, Dermatology, Pharmacotherapy +14

Guselkumab, an anti‐interleukin‐23 monoclonal antibody, for the treatment of moderate to severe plaque‐type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double‐blind, placebo‐controlled study

Mamitaro Ohtsuki, Hiroshi Kubo, Hitomi Morishima et al. · The Journal of Dermatology · 2018 · 109 citations · Full text

Medicine, Dermatology, Pharmacotherapy +12

Efficacy and Safety of Guselkumab in Japanese Patients With Palmoplantar Pustulosis

Tadashi Terui, Satomi Kobayashi, Yukari Okubo et al. · JAMA Dermatology · 2019 · 102 citations · Full text

Medicine, Dermatology, Pharmacotherapy +14

Sustained efficacy and safety of guselkumab in patients with palmoplantar pustulosis through 1.5 years in a randomized phase 3 study

Yukari Okubo, Hitomi Morishima, Richuan Zheng et al. · The Journal of Dermatology · 2021 · 32 citations · Full text

Medicine, Pharmacotherapy, Antimicrobial Pharmacotherapy +12

Transmitochondrial mito-miceΔ and mtDNA mutator mice, but not aged mice, share the same spectrum of musculoskeletal disorders

Takayuki Mito, Hikari Ishizaki, Michiko Suzuki et al. · Biochemical and Biophysical Research Communications · 2014 · 12 citations · Full text

Life Sciences, Genetics, Molecular Genetics +13